 |
List of Publications |
 |
|
| |
B1. ORIGINAL ARTICLES
1. Inbar MJ, Baratz M, Figer A, Schpitzer-Reter E, Chaitchik S
Idiosyncratic reaction to bleomycin in an epithelial tumor
Cancer Chemother Pharmacol; 13: 71-72, 1984
2. Baram A, Figer A, Inbar M, Levy E, Peyser MR, Stein Y
Endometrial carcinoma stage I-comparison of two different treatment
regimes-evaluation of risk factors and its influence on prognosis; suggested step by step treatment protocol
Gynecol Oncol; 22: 294-301, 1985
3. Rozen P, Fireman Z, Figer A, Ron E
Colorectal tumor screening in women with a past history of breast,
uterine, or ovarian malignancies
Cancer; 57: 1235-1239, 1986
4.Rozen P, Lynch HT, Figer A, Rozen S, Fireman Z, Legum C, Katz L, Moy A,
Kimberling W, Lynch J
Familial colon cancer in the Tel-Aviv area and the influence of ethnic
origin
Cancer; 60: 2355-2359, 1987
5. Rozen P, Fireman Z, Figer A, Legum C, Ron E, Lynch HT
Family history of colorectal cancer as a marker of potential malignancy
within a screening program
Cancer; 60: 248-254, 1987
6. Rahima M., Luria H., Figer A., Levin I., Klein B.
Solitary spleen metastasis in breast carcinoma
The J of Bloodless Medicine and Surgery (JBMS) 8;20-21, 1990.
7. Klein B., Klein T., Figer A., Shapira J., Livni E., Lurie H, Levin I.
Soluble HLA class I in colon cancer.
The Cancer Journal, 1991, 4:322-325
8. Klein B, Klein T, Figer A, Bleiberg M, Shapira J, Loven D, Livni E, Lurie H, Niska A
Soluble histocompatibility antigen class I in breast cancer patients in
relation to tumor burden
Cancer; 67:2295-2299, 1991
9. Trattner A, Figer A, David M, Lurie H, Sandbank M
Circumscribed scleroderma induced by postlumpectomy radiation therapy
Cancer; 68: 2131-2133, 1991
10. Klein B, Klein T, Nyska A, Shapira J, Figer A, Schwartz A, Rakovsky E, Livni E, Lurie H
Expression of HLA class I and class II in gastric carcinoma in relation to
pathologic stage
Tumour Biol; 12:68-74, 1991
11. Gez E, Wygoda M, Nussbaum N, Figer A, Gil Rl, Inbal M
Surveillance in patients with stage I testicular nonseminomatous germ cell
tumors
Cancer Invest; 11:10-14, 1993
12. Cohen I, Beyth Y, Tepper R, Figer A, Shapira J, Cordoba M, Yigael D, Altaras MM
Adenomyosis in postmenopausal breast cancer patients treated with
tamoxifen: a new entity?
Gynecol Oncol; 58:86-91, 1995
13. Cohen I, Figer A, Altaras MM, Tepper R, Shapira J, Cordoba M, Yigael D,
Arbel Y, Beyth Y
Common endometrial decidual reaction in postmenopausal breast cancer
patients treated with tamoxifen and progestogens
Int J Gynecol Pathol; 15:17-22, 1996
14. Cohen I, Beyth Y, Tepper R, , Shapira J, Zalel Y, Figer A, Cordoba M,
Yigael D, Altaras MM
Ovarian tumors in postmenopausal breast cancer patients treated with
tamoxifen
Gynecol Oncol; 60:54-58, 1996
15. Cohen I, Altaras MM, Shapira J, Tepper R, Rosen DJ, Cordoba M, Zalel Y,
Figer A,Yigael D, Beyth Y
Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients
Int J Gynecol Pathol; 15:152-157, 1996
16. Cohen I, Beyth Y, Tepper R, Figer A, Shapira J, Cordoba M, Yigael D,
Altaras MM
Adenomyosis in postmenopausal breast cancer patients treated with
tamoxifen: a new entity?
Gynecol Oncol 61: 159-160, 1996
17. Cohen I, Beyth Y, Altaras MM, Shapira J, Tepper R, Cordoba M, Yigael D,
Figer A, Fishman A, Berenhein J
Estrogen and progesterone receptor expression in postmenopausal
tamoxifen-exposed endometrial pathologies
Gynecol Oncol; 67:8-15, 1997
18. Cohen I, Altaras MM, Beyth Y, Shapira J, Figer A, Tepper R, Cordoba M,
Yigael D, Berenhein J
Estrogen and progesterone receptors in the endometrium of
postmenopausal breast cancer patients treated with tamoxifen and
progestogens
Gynecol Oncol; 65:83-88, 1997
19. Cohen I, Altaras MM, Shapira J, Tepper R, Cordoba M, Figer A, Zalel Y,Dror Y, Beyth Y
Different coexisting endometrial histological features in asymptomatic
postmenopausal breast cancer patients treated with tamoxifen
Gynecol Obstet Invest; 43:60-63, 1997
20. Cohen I, Beyth Y, Bernheim J, Shapira J, Cordoba M, Aviram R, Figer A,
Yigael D, Altaras MM
Different coexisting gynecological and endometrial pathologies in
postmenopausal breast cancer patients treated with tamoxifen
Gynecol Obstet Invest; 46:123-129, 1998
21. Figer A., Klein B., Mishaeli M., Sadikov E., Kfir B., Narniski R., Klein T.
Superoxide dismutase activity in colon cancer patients
International Proceedings Cancer
Monduzzi Editore, p. 1001-1004, 1998
22. Klein B., Figer A., Mishaeli M., Sadikov E., Bayer I., Estlein D., Narinsky R
Allelic loss (L.O.H) of chromosome 18q in colorectal cancer
International Proceedings Cancer
Monduzzi Editore, p. 255-257, 1998
23. Niv Y, Sperber AD, Figer A, Igael D, Shany S, Fraser G, Schwartz B
In colorectal carcinoma patients, serum vitamin D levels vary according to stage of the Carcinoma
Cancer; 86:391-397, þþ1999
24. Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yigael D, Beyth Y
Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: Comparison between tamoxifen-treated and nontreated breast cancer patients
Gynecol Oncol; 72:202-207, 1999
25. Greif F, Rubin M, Mor E, Nudelman I, Cyjon A, Figer A, Belinki A,
Lelchuck Sh
Liver surgery-five years of experience
Harefuah- 136:6, 1999
26. Patael Y, Figer A, Gershoni-Baruch R, Z Papa M, Risel Sh, Shtoyerman-Chen R, Karasik A, Theodor L, Friedman E
Common origin of the I1307K APC polymorphism in Ashkenazi and
non-Ashkenazi Jews
European Journal of Human Genetics 555-559, 1999
27. Cohen I, Tepper R, Figer A, Flex D, Shapira J, Beyth Y
Successful co-treatment with LHRH-agonist for ovarian over-stimulation
and cystic formation in premenopausal tamoxifen exposure
Breast Cancer Research and Treatment 55:119-125, 1999
28. Nahari C, Tepper R, Beyth Y, Flex D, Figer A, Cohen I
Long-Term Transvaginal Ultrasonographic Endometrial Follow-up in
Postmenopausal Breast Cancer Patients with Tamoxifen Treatment
Gynecol Oncol 74, 222-226, 1999
29. Cohen I., Perel E., Tepper R., Flex D., Figer A., Shapira J., Altaras MM., Fishman A., Bernheim J., Cordoba M., Yigael D., Beyth Y.
Dose-dependent effect of tamoxifen therapy on endometrial pathologies
in postmenopausal breast cancer patients.
Breast Cancer Research and Treatment 53, 255-262, 1999
30. Chausovsky G., Luchansky M., Figer A., Shapira J., Gottfried M., Novis B., Bogelman G., Zemer R., Zimlichman Sh., Klein A.
Expression of Cytokeratin 20 in the Blood of Patients with Disseminated
Carcinoma of the Pancreas, Colon, Stomach, and Lung
Cancer 86: 2398-2405, 1999
31. Gershoni-Baruch R., Patael Y., Dagan E., Figer A., Kasinetz L., Kadouri E., Chetrit A., Bruchim Bar Sade R., Kruglikova A., Papa MZ., Rizel S., Karasik A, Friedman E.
Association of the 11307K APC mutation with hereditary and sporadic
breast/ovarian cancer: more questions than answers.
Br J Cancer 83:153-5, 2000.
32. Klein B., Sadikov E., Mishaeli M., Levin I., Figer A.
Comparison of 5-FU and leucovorin to gemcitabine in the treatment of
pancreatic cancer
Rabin Medical Center, Oncology Unit, Golda Campus; Institute of Oncology,
Beilinson Campus, Petach Tikva and the Sackler Faculty of Medicine, Tel-Aviv
University, Israel-February 21, 2000.
33. Gershoni-Baruch R, Patael Y, Figer A, Dagan E, Chetrit A, Bruchim Bar Sade R, Kruglikova A, Z. Papa M, Risel Sh, Karasik A, Friedman E
The I1307K APC mutation co-occurs in 10% of Jewish women with the
predominant Jewish germline mutations in BRCA1 and BRCA2
European Journal of Human Genetics
34. Patal Y., Figer A., Gershoni-Baruch R., Papa M.Z., Risel S., Chen R.,
Karasik A., Theodor L.,Friedman E.
The I1307K APC mutation in Non-Ashkenazi Jews
A common origin of the I1307K APC polymorphism in Ashkenazi and non-Ashkenazi Jews.
Eur J Hum Genet 7:555-559, 1999
35. De Gramont A., Figer A., Seymour M., Homerin M., Hmissi A., Cassidy J., Boni C., Cortes-Funes H., Cervantes A., Freyer G., Papamichael D., Le Bail N., Louvet C., Hendler D., De Braud F., Wilson C., Morvan F., Bonetti A.
Leucovorin and Fluorouracil with or without Oxaliplatin as first-line
treatment in advanced colorectal cancer
Journal of Clinical Oncology, Vol 18, Issue 16 (August), 2000: 2938-2947
36. Cohen I., Beyth Y., Azaria R., Flex D., Figer A., Tepper R MD
Ultrasonographic endometrial changes following discontinuation of
tamoxifen treatment in postmenopausal breast cancer patients.
Brit J Obstet Gynecol 107:1083-1087, 2000
37. Figer A., Sadikov E., Mishaeli M., Koren R., Gal R., Levin I., Klein B.,
A Comparison of Two Dose Regimens in Pancreatic Cancer.
Journal of Chemotherapy Vol.12 – n. 5 (442-445), 2000
38. Chen Shtoyerman R, Figer A, Fidder HH, Rath P, Yeremin L, Bar Meir S, Theodor L, Friedman E
The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi Colorectal cancer patients
Brit J of Cancer, 84:475-477, 2001
39. Figer A., Yeremin L., Geva R., Flex D., Soulkes A., Friedman E.
The rate of the 6174delT founder Jewish mutation in BRCA2 in patients
with non-colon gastrointestinal tumors in Israel From the Institute of Oncology Rabin Medical Center (Belinson Canpus),
Petach Tikvah, (A.F., L.Y.R.G., D.F., &A.S); the Susanne Levy Gertner
Oncogeneties Unit (L.Y & E.F), Chaim Sheba Medical Center, Tel-Hashomer,62521, and the Sackler school of Medicine, Tel-Aviv University,
Tel-Aviv. Israel.
40. Cohen I, Beyth Y, Azaria R, Flex D, Figer A, Tepper R
Ultrasonographic endometrial changes following discontinuation of tamoxifen treatment in postmenopausal breast cancer patients.
Brit J Obstet Gynecol: 107; 1083-1087, 2,000
B2. Case Report
1. Figer A, Brener B, Njuguna E, Katz A, Sulkes A
Umbilical Metastases of gall bladder carcinoma unrelated to a laparoscopic
Procedure
Digestive disease and science, 45:1058-1060, June 2000.
B3. Review Article
1. Figer A, Nusbaum B, Sulkes A
Testicular seminoma –consensus and controversies
Harefuah; 123: 423-425, 1992
H. Submitted for publication:
1. Koehne H, Catane R, Klein B, Ducreux M, Niederle N, Peretz T, Preusser P, Knuth A, Clemens M, Bugat R, Figer A, Shani A, Fages B, Di Betta D, Wilke H.J., Jacques C
Irinotecan is active in the treatment of patients with metastatic gastric
cancer without prior chemotherapy: a single agent phase II multicentric
trial
2. Tepper R, Beyth Y, Shapira J, Figer A, Altaras MM, Dror Y, Cohen I
Postmenopausal ovarian volume in breast cancer patients treated with
various types of adjuvant therapy.
J Ultrasound Med
3. Cohen I, Nahari C, Beyth Y, Flex D, Figer A, Tepper R
Long-term follow-up of ovarian volume in postmenopausal breast cancer patients with tamoxifen treatment.
Ultrasound Obstet Gynecol
4. Cohen I, Flex D, Nahari C, Figer A, Dror Y, Sharony R, Beyth Y, Bernheim J
The association between positive breast cancer estrogen and progesterone
receptors and the development of endometrial pathologies in postmenopausal tamoxifen-treated patients. Cancer
5. Figer A., Sadikov E., Mishaeli M., Koren R., Gal R., Sulkes A., Klein Is modulation of 5-FU and leucovorin important in the treatment of
pancreatic cancer?
Rabin Medical Center Institute of Oncology, Campus Beilinson 2 Oncology Unit, Campus Golda, Department of Pathology, Campus Golda Petach-Tikva, Israel
6. Tichler T., Klein B., Sadikov E., Mishaeli M., Ghodsizade E., Kutten A., Shapira J., Daud K., Zen el Din I., Hendler D., Figer A.
Weekly high dose 5-Fluorouracil and leucovorin in the treatment of
advanced colorectal cancer patients refractory to standard 5-FU +
Leucovorin From the Departments Oncology:
Sheba Medical Center, Rabin Medical Center, Golda Campus and Belinson
Campus, Rambam Medical Center, Meir Hospital, Italian hospital of Haifa and
the Tel-Aviv University Sackler School of Medicine, Israel, and Bruno
Rappaport faculty of medicine, Technion, Haifa, Israel
7. Figer A., Patael Karasik Y., Gershoni Baruch R., Chetrit A., Z Papa M., Bruchim Bar Sade R., Riezel Sh., Friedman E.
Insulin like growth factor I (IGF-I) polymorphism and breast cancer risk
in Jewish women
8. Tepper R., Beyth Y., Shapira J., Figer A., Altaras MM., Dror Y., Cohen I.
Postmenopausal ovarian volume in breast cancer patients treated with
various types of adjuvant therapy.
J Ultrasound Med
9. Cohen I., Nahari C., Beyth Y., Flex D., Figer A., Tepper R.
Long-term follow-up of ovarian volume in postmenopausal breast cancer
patients with tamoxifen treatment.
Ultrasound Obstet Gynecol
10. Cohen I., Flex D., Nahari C., Figer A., Dror Y., Sharony R., Beyth Y., Bernheim J.
The association between positive breast cancer estrogen and progesterone
receptors and the development of endometrial pathologies in postmenopausal tamoxifen-treated patients.
Brit J Obstet Gynecol
In Press
1. Sverdlov S., Bruchim Bar Sade R., Gershoni Baruch R., Barshack I., Hirsh Yehezkel G., Dagan E., Feimesser M., Figer A., Friedman E.
Male Breast cancer
Genetic analyses of male breast cancer in Israel. Genetic Testing, 2000.
2. Shtoyerman-Chen R, Figer A, Friedman E, Carmel M, Patael Y, Rath P, H. Fidder H, Bar-Meir S, Theodor L
The I1307K APC Polymorphism: Prevalence in non-Ashkenazi Jews and
Evidence for a Founder Effect
Genetics Testing
3. Figer A., Irmin L., Geva R., Flex D., Sulkes A., Friedman E.
Genetic analysis of the APC gene regions involved in attenuated APC phenotype in Israeli patients with early onset and familial colorectal cancer
B4. CHAPTER IN BOOKS
1. P. Rosen, Z. Fireman, A. Figer, C. Legum, H.T. Lynch
The Relevance of the Family History of Cancer in a Screening Program
for Large Bowel Tumors.
Frontiers of Gastrointestinal Research, pp. 195-205.
|
|
|
|
|
